Labeler · US market

Pacira Pharmaceuticals, Inc.

Pacira Pharmaceuticals, Inc. is a US drug labeler with US FDA registrations covering 2 drug concepts (2 currently active) across 5 packages. It is currently the only active US supplier of 1 drug.

ACTIVE — US

openFDA · updated weekly

Labeler codes65250

Active drugs2

Registrations3 active / 3

Packages5

Sole supplier of1 drugs

Portfolio2 drugs · US

Every drug concept this labeler has US registrations for, by package count.

Drug	Type	NDCs	Packages	Status
Bupivacaine injection, suspension, liposomal	rx	2	4	SUPPLYING
Triamcinolone Acetonide Extended-Release Injectable Suspension kit	rx	1	1	SUPPLYING

Sole US supplier

Drugs where this labeler is currently the only active US supplier — a single point of failure if it exits.

Triamcinolone Acetonide Extended-Release Injectable Suspensionrx

At a glance

TypeLabeler
Labeler codes65250
Filing names1
Drugs (active)2
Drugs (all time)2
US registrations3
Packages5

Recent events

Shortages, recalls, and registration changes across all filing names.

Jun 12, 2024
RECALLRecall (Class II): Zilretta (triamcinolone acetonide extended-release injectable suspension), 32 mg per vial, Rx only, Manufactured for: P…
May 7, 2024
RECALLRecall (Class II): Drug Vial Label: Zilretta¿ (triamcinolone acetonide extended-release injectable suspension), 32 mg per vial, Rx only, M…
Nov 21, 2019
RECALLRecall (Class II): EXPAREL, Bupivicaine Liposome Injectable Suspension, 1.3%, 266 mg/20 mL (13 mg/mL), Sterile, 20 mL vial, Rx only, Manuf…
Dec 17, 2012
RECALLRecall (Class II): EXPAREL (bupivacaine liposome injectable suspension), 1.3%, 266 mg/20 mL (13.3 mg/mL) single use vials, INVESTIGATIONA…

Watch this company

Alerts for recalls, exits, and new registrations.

Facility locations, FDA inspections, and parent-company mapping are on the roadmap. Name variants reported to FDA under different spellings are merged into this profile; figures cover the entity across all its filing names.